Lonza published its Q3 qualitative statement. The group confirmed its outlook for FY17 for Lonza on a standalone basis, which was upgraded in April (high single-digit top-line growth, a core EBITDA level of above CHF1bn, double-digit CORE EBIT growth significantly above sales growth). The integration of Capsugel is said to be on track to deliver expected synergies and growth targets.
26 Oct 2017
Q3 statement: everything looks ok but our target is almost reached
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q3 statement: everything looks ok but our target is almost reached
Lonza Group AG (0QNO:LON) | 0 0 0.0% | Mkt Cap: 22,735m
- Published:
26 Oct 2017 -
Author:
Fabrice Farigoule -
Pages:
2
Lonza published its Q3 qualitative statement. The group confirmed its outlook for FY17 for Lonza on a standalone basis, which was upgraded in April (high single-digit top-line growth, a core EBITDA level of above CHF1bn, double-digit CORE EBIT growth significantly above sales growth). The integration of Capsugel is said to be on track to deliver expected synergies and growth targets.